{"id":85901,"date":"2013-06-28T03:51:53","date_gmt":"2013-06-28T07:51:53","guid":{"rendered":"http:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/uncategorized\/ibc-and-penn-medicine-team-to-study-medication-adherence-genomic-cancer-and-more.php"},"modified":"2013-06-28T03:51:53","modified_gmt":"2013-06-28T07:51:53","slug":"ibc-and-penn-medicine-team-to-study-medication-adherence-genomic-cancer-and-more","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/medicine\/ibc-and-penn-medicine-team-to-study-medication-adherence-genomic-cancer-and-more.php","title":{"rendered":"IBC and Penn Medicine Team to Study Medication Adherence, Genomic Cancer, and More"},"content":{"rendered":"<p><p>    PHILADELPHIA,    PA--(Marketwired - June 27, 2013) -    Independence Blue Cross (IBC) announces a new    collaboration with Penn Medicine today on research initiatives    into some of today's most pressing health issues. Current    research studies are underway to:  <\/p>\n<p>    Future research studies are in the planning stage to:  <\/p>\n<p>    \"Philadelphia should be the Silicon Valley of health care    innovation given its active investment community and pool of    talent with experience in the health care field,\" said IBC    president and CEO Daniel J. Hilferty. \"Penn is one of the    nation's premier research universities and our two    organizations have enjoyed a long relationship of working    together to improve the health of people in our community. We    are excited about this new research initiative, which, among    many things, will help us learn more about ways to change    behaviors to improve health outcomes and lower health care    costs.\"  <\/p>\n<p>    \"We saw IBC as a natural partner for Penn because of its high    quality informatics capabilities,\" said University of    Pennsylvania Health System CEO Ralph Muller. \"We've enjoyed    collaborating with IBC on a number of initiatives, as we    believe that combining resources and perspectives across the    leading payer and provider in the region creates opportunities    for meaningful innovation.\"  <\/p>\n<p>    In one study, researchers will look at whether pill bottles    equipped with beeping devices that alert patients to take their    medications -- in addition to a series of behavioral economic    motivational tools -- will improve medication adherence. This    study also examines how a social support system can improve    drug adherence in patients discharged from a hospital after a    heart attack.  <\/p>\n<p>    \"One of the greatest challenges to improving health care today    centers on changing the behaviors that lead to poor health,    whether that is eating right and exercising, getting    appropriate tests and screenings, or taking the medications    doctors prescribe,\" said Kevin Volpp, M.D., Director of the    Center for Health Incentives and Behavioral Economics at the    University of Pennsylvania, who is overseeing several of the    research projects. \"Evidence shows that patients who take    medications such as cholesterol lowering drugs as prescribed    have a much lower likelihood of being readmitted to the    hospital or having another heart attack. We know that there are    tremendous health benefits to increasing medication adherence    and improving health behaviors to reduce patients' risk of    disease. It's just a matter of figuring out the best ways to    achieve the desired behaviors,\" added Volpp.  <\/p>\n<p>    \"We're excited about leveraging our powerful technology and    informatics capabilities with Penn to find new ways to address    serious health issues,\" said Somesh Nigam, senior vice    president and chief informatics officer of IBC. \"The long-term    potential for this work to improve our members' health, as well    as the health of others throughout our community, is    significant.\" Somesh added that all patient data IBC provides    for the research will comply with HIPAA regulations and will be    securely maintained at all times.  <\/p>\n<p>    While these are primarily multi-year studies, Nigam expects    that there could be some preliminary results for the genomic    testing project in early 2014.  <\/p>\n<p>    About Independence Blue CrossProudly    celebrating its 75th anniversary in 2013,     Independence Blue Cross is the leading health insurer in    southeastern Pennsylvania serving more than seven million    people nationwide, including 2.2 million in the region. We are    enhancing the health and wellness of the people and communities    we serve by delivering innovative and competitively priced    health care products and services; pioneering new ways to    reward doctors, hospitals, and other health care professionals    for coordinated, quality care; and supporting programs and    events that promote wellness. To learn more about how we're    changing the game, visit     <a href=\"http:\/\/www.ibx.com\" rel=\"nofollow\">http:\/\/www.ibx.com<\/a>. Connect with us on Facebook at     ibx.com\/facebook and on Twitter at     @ibx. Independence Blue Cross is an independent licensee of    the Blue Cross and Blue Shield Association.  <\/p>\n<p><!-- Auto Generated --><\/p>\n<p>Read the rest here: <\/p>\n<p><a target=\"_blank\" href=\"http:\/\/finance.yahoo.com\/news\/ibc-penn-medicine-team-study-161727621.html;_ylt=AwrNUWx9QM1R4WUACgD_wgt.\" title=\"IBC and Penn Medicine Team to Study Medication Adherence, Genomic Cancer, and More\">IBC and Penn Medicine Team to Study Medication Adherence, Genomic Cancer, and More<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> PHILADELPHIA, PA--(Marketwired - June 27, 2013) - Independence Blue Cross (IBC) announces a new collaboration with Penn Medicine today on research initiatives into some of today's most pressing health issues. Current research studies are underway to: Future research studies are in the planning stage to: \"Philadelphia should be the Silicon Valley of health care innovation given its active investment community and pool of talent with experience in the health care field,\" said IBC president and CEO Daniel J <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/medicine\/ibc-and-penn-medicine-team-to-study-medication-adherence-genomic-cancer-and-more.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[35],"tags":[],"class_list":["post-85901","post","type-post","status-publish","format-standard","hentry","category-medicine"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/85901"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=85901"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/85901\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=85901"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=85901"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=85901"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}